A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer

BMC Cancer

Table 1 Clinical and pathological characteristics of the prostate cancer datasets used in this study

	MSKCC (Taylor et al.) n = 140	Cambridge (Ross-Adams et al.) n = 112	Stockholm (Ross-Adams et al.) n = 92	TCGA-PRAD (TCGA) n = 490
Age (years)
Mean	58.04	62		61
Range	37.3–83.0	41–73		41–78
PSA
Median	6.15	7.9	7.95
< 10	104	80	56
≥ 10	34	31	34
Unknown	2	1	2
Biopsy Gleason
≤ 3 + 4	128	77	68
≥ 4 + 3	12	27	22
Unknown		8	2
Surgical Gleason
≤ 3 + 4	94	83	56	197
≥ 4 + 3	44	29	34	293
Unknown	2		2
Extra-capsular ext.				(mri + ct scan combined)
Y	97	77	42	31
N	43	35	48	199
NA/equivocal			2	260
Positive surgical margins
Y	33	26	42	165
N	107	86	50	311
Unknown				14
Recurrence
Y	36	19	45	91
N	104	93	47	399
Pathology Stage
pT2a-c	87	35	47	184
pT3a-c	46	77	42	290
pT4	7		3	10
Unknown				6

The table defines the characteristics of the samples used in this study for each of the datasets

ISSN: 1471-2407